Contact
searchSearch
HMP Global
Login

Hodgkin Lymphoma Specialty Channel

News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024
Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
From Oncology
News
Treatment Strategies for Advanced Classic Hodgkin Lymphoma
07/08/2022
Ellen Kurek
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies...
07/08/2022
Journal of Clinical Pathways
Stephen Ansell, MD, PhD
Interview
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma
06/14/2022
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD,...
06/14/2022
Journal of Clinical Pathways
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
01/14/2021
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD,...
01/14/2021
Journal of Clinical Pathways
FDA Expands Approval of Pembrolizumab for Classical Hodgkin Lymphoma
FDA Alerts
FDA Expands Approval of Pembrolizumab for Classical Hodgkin Lymphoma
10/15/2020
The FDA expanded the approval of pembrolizumab to include adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy.
The FDA expanded the approval of pembrolizumab to include adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy.
The FDA expanded the approval of...
10/15/2020
Journal of Clinical Pathways
News
Reducing Cause-Specific Mortality in Classical Hodgkin Lymphoma
10/14/2020
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early...
10/14/2020
Journal of Clinical Pathways
News
Assessing Frequency of Secondary Malignancies in Survivors of Hodgkin Lymphoma
06/17/2020
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study...
06/17/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Monotherapies for Relapsed, Refractory Hodgkin Lymphoma
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways

Expert Insights

Stephen Ansell, MD, PhD
Interview
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma
06/14/2022
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD,...
06/14/2022
Journal of Clinical Pathways
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
01/14/2021
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD,...
01/14/2021
Journal of Clinical Pathways
Houda Hachad, PharmD
Interview
FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
03/26/2025
Houda Hachad, PharmD
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US...
03/26/2025
Journal of Clinical Pathways
Upal Basu Roy, PhD, MPH
Interview
Project PRIORITY: Elevating the Patient Voice in EGFR-Positive NSCLC Care
03/24/2025
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu...
03/24/2025
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
03/24/2025
F. Randy Vogenberg, PhD, FASHP
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
03/24/2025
Journal of Clinical Pathways
Kohli Headshot
Interview
Strengthening Patient Pathways With BIS for Lymphedema Surveillance
03/24/2025
Manpreet Kohli, MD
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet...
03/24/2025
Journal of Clinical Pathways
Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Advancing Value-Based Oncology With the Predictable Cost of Care Working Group: Part 2
03/17/2025
Gordon Kuntz; Carole Tremonti, RN, MBA
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology...
03/17/2025
Journal of Clinical Pathways
Brian S.
Interview
Key Advancements in Immunotherapy for Endometrial Cancer
03/13/2025
Brian M. Slomovitz, MD, MS
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses...
03/13/2025
Journal of Clinical Pathways
Brufsky Headshot
Interview
Transforming Metastatic Breast Cancer Care With AI and Real-World Evidence
03/11/2025
Adam Brufsky, MD, PhD
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky,...
03/11/2025
Journal of Clinical Pathways

Newsfeed

News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024
Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
News
Treatment Strategies for Advanced Classic Hodgkin Lymphoma
07/08/2022
Ellen Kurek
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies...
07/08/2022
Journal of Clinical Pathways
News
Reducing Cause-Specific Mortality in Classical Hodgkin Lymphoma
10/14/2020
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early...
10/14/2020
Journal of Clinical Pathways
News
Assessing Frequency of Secondary Malignancies in Survivors of Hodgkin Lymphoma
06/17/2020
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study...
06/17/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Monotherapies for Relapsed, Refractory Hodgkin Lymphoma
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Evaluating the Cost Benefits and Clinical Potential of Serum Pepsinogen Screening for Gastric Cancer
03/07/2025
Juliet Gallagher
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in...
03/07/2025
Journal of Clinical Pathways
News
Strategies to Enhance Cancer Screening Access for Patients With Disabilities
03/06/2025
Juliet Gallagher
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face...
03/06/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Ruxolitinib Prior to Transplantation Linked to Better Survival in Myelofibrosis
03/05/2025
Grace Taylor, MS, MA
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of...
03/05/2025
Journal of Clinical Pathways

Interactive Features

SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024
Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
News
Treatment Strategies for Advanced Classic Hodgkin Lymphoma
07/08/2022
Ellen Kurek
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies...
07/08/2022
Journal of Clinical Pathways
Stephen Ansell, MD, PhD
Interview
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma
06/14/2022
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD,...
06/14/2022
Journal of Clinical Pathways
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
01/14/2021
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD,...
01/14/2021
Journal of Clinical Pathways
FDA Expands Approval of Pembrolizumab for Classical Hodgkin Lymphoma
FDA Alerts
FDA Expands Approval of Pembrolizumab for Classical Hodgkin Lymphoma
10/15/2020
The FDA expanded the approval of pembrolizumab to include adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy.
The FDA expanded the approval of pembrolizumab to include adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy.
The FDA expanded the approval of...
10/15/2020
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use